![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ARCHEMIX ANNOUNCES STRATEGIC ALLIANCE WITH ELAN TO DISCOVER AND DEVELOP APTAMER THERAPEUTICS
ARCHEMIX ANNOUNCES STRATEGIC ALLIANCE WITH ELAN TO DISCOVER AND DEVELOP APTAMER THERAPEUTICS
July 13, 2006
Archemix Corp. announced today a multi-year, multi-product alliance with Elan Corporation, plc focused on the discovery, development, and commercialization of first-in-class aptamer therapeutics to treat autoimmune disease. The companies will seek to develop
aptamer therapeutics to IL-23, a cytokine that has emerged as a mediator in the
chronic autoimmune inflammatory diseases, and additional protein targets.
Drug
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct